NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Teva's financial performance decreased due to lower revenues in North America and impacted by legal settlements and loss contingencies.

Teva reported a decrease in revenues and a GAAP diluted loss per share, mainly due to lower revenues in North America and legal settlements. However, it saw gains in market share for AJOVY in the United States and Europe and reaffirmed its earnings and cash flow guidance.

  • Revenues decreased by 8% to $3.7 billion compared to Q1 2021.
  • GAAP diluted loss per share was $0.86.
  • Non-GAAP diluted EPS was $0.55.
  • Free cash flow was $117 million.

Headline financials

Total Revenue

$3.66B

Previous: $3.98B-8.1%
EPS (adj)

$0.55

Previous: $0.63-12.7%
Adjusted EBITDA

$1.14B

No prior period
Capital Expenditures

-$157M

Previous: -$150M-4.7%
Free Cash Flow

-$1.11B

Previous: -$73M-1423.3%
Net Income

-$955M

Previous: $77M-1340.3%
Operating Income

-$713M

Previous: $434M-264.3%
Gross Profit

$1.74B

Previous: $1.88B-7.3%
Cash & Equivalents

$2.18B

Previous: $1.74B+24.8%
Total Assets

$47.1B

Previous: $49B-4.0%
Stock-Based Comp

$24M

Previous: $31M-22.6%

Revenue & EPS history

Teva · Revenue · Quarterly

$3.66B

Q1 2022-8.1%vs Q1 2021
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

Teva · $3.56B total across 4 segments · Q1 2022

  • United States
    $1.64B
  • Europe
    $1.16B
  • International Markets
    $492M
  • Other Activities
    $275M

Forward guidance

Teva revised its 2022 revenue outlook lower due to foreign exchange fluctuations and increased competition for COPAXONE, while reaffirming its earnings and cash flow guidance.

Tailwinds

  • Revenues of $15.4 - $16.0 billion
  • Adjusted EBITDA of $4.7 - $5.0 billion
  • Non-GAAP diluted EPS of $2.40 - $2.60
  • Free cash flow of $1.9 - $2.2 billion
  • Non-GAAP Tax Rate 18% - 19%

Headwinds

  • Revenues outlook revised lower due to ongoing impact of foreign exchange fluctuations.
  • COPAXONE revenues of approximately $750 million vs. previous outlook of approximately $850 million
  • COPAXONE outlook revised lower mainly to reflect increased competition and foreign exchange fluctuations.
  • Share Count 1,114 million shares
  • CAPEX 0.6

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro